OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)Jinlin Hou, Tarik Asselah, Qing Xie et al.|Journal of Hepatology|2024Cited by 8
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trialMingyuan Zhang, Junqi Niu, Yongning Xin et al.|Journal of Infection|2025Cited by 6
LBP-014 HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb studyYanhang Gao, Junqi Niu, Xieer Liang et al.|Journal of Hepatology|2025Cited by 2